Corvus director granted options on 15,000 shares
Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corvus Pharmaceuticals director Richard van den Broek received a new stock option grant. On the reported date, he was awarded options to buy 15,000 shares of Corvus common stock at an exercise price of $11.60 per share. All 15,000 options vest in a single tranche on the earlier of the first anniversary of the grant or the company’s 2027 annual stockholder meeting, assuming he continues serving as a director until that vesting date.
Insider Trade Summary
Grant/Award: 15,000 shares
Grant/Award
1 txn
Insider
van den Broek Richard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 contracts (Direct)
Footnotes (1)
- F1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Key Figures
Option grant size: 15,000 options
Exercise price: $11.60 per share
Underlying shares: 15,000 shares
+2 more
5 metrics
Option grant size
15,000 options
Stock Option (Right to Buy) awarded to director
Exercise price
$11.60 per share
Conversion or exercise price of granted options
Underlying shares
15,000 shares
Common Stock underlying the option grant
Expiration date
2036-06-11
Option expiration for the 15,000-share grant
Shares following transaction
15,000 options
Total derivative securities after this award
Key Terms
Stock Option (Right to Buy), exercise price, underlying security, Annual Meeting of the Issuer's stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "11.6000" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: "Common Stock" with 15,000 shares"
Annual Meeting of the Issuer's stockholders regulatory
"earlier of the first anniversary or the 2027 Annual Meeting"
vesting financial
"shares subject to the option vest and become exercisable as to 100%"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corvus Pharmaceuticals (CRVS) director Richard van den Broek receive in this Form 4?
He received a stock option grant for 15,000 shares of Corvus common stock. The options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the new Corvus (CRVS) stock options?
The options have an exercise price of $11.60 per share for 15,000 underlying common shares. This price is the cost per share he must pay to exercise the options once they are vested and exercisable, according to the Form 4 disclosure.
When do Richard van den Broek’s new Corvus (CRVS) options vest?
The 15,000 options vest 100% on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting. Vesting is contingent on his continuous service as a director through that vesting date, as described in the footnote.
Is this Corvus (CRVS) Form 4 an insider stock purchase or a compensation award?
This filing reports a compensation-related award, not an open-market stock purchase. The code “A” and description show it is a grant of stock options, providing rights to buy shares later rather than an immediate acquisition of common stock in the market.
How many Corvus (CRVS) derivative securities does the director hold after this transaction?
After the grant, the Form 4 shows 15,000 stock options following the reported transaction. These options are derivative securities tied to 15,000 underlying shares of common stock and become exercisable only after the specified vesting conditions are satisfied.
AI-generated analysis. How Rhea-AI works. Not financial advice.
